Progressive Supranuclear Palsy Market

Progressive Supranuclear Palsy is a class of neuro-degenerative disorder that affects movement, control of walking and balance, speech, swallowing, vision, mood and behavior, and thinking.

Progressive Supranuclear Palsy Market contains market size and forecasts of Progressive Supranuclear Palsy in Global, including the following market information:

• Global Progressive Supranuclear Palsy Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Progressive Supranuclear Palsy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Early Stage Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Progressive Supranuclear Palsy include Merck & Co., Inc., Aton Pharma, Inc., Bristol Myers Squibb (BMS), GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., AB Science, AbbVie Inc. and AlzProtect SAS, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Progressive Supranuclear Palsy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Progressive Supranuclear Palsy Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Progressive Supranuclear Palsy Market Segment Percentages, by Type, 2021 (%)

• Early Stage
• Clinical Trial
• Late Stage
• Others

Global Progressive Supranuclear Palsy Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Progressive Supranuclear Palsy Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Research Institutes
• Others

Global Progressive Supranuclear Palsy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Progressive Supranuclear Palsy Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Progressive Supranuclear Palsy revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Progressive Supranuclear Palsy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Merck & Co., Inc.
• Aton Pharma, Inc.
• Bristol Myers Squibb (BMS)
• GlaxoSmithKline plc
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• AB Science
• AbbVie Inc.
• AlzProtect SAS
• Cortice Biosciences, Inc.
• Acorda Therapeutics Inc.
• Biogen Inc.